Clinical Trials: Clinical Trials in India

Managing CDSCO Filings for Clinical Trial Amendments in India

Posted on digi By digi

Clinical trial amendments are an inevitable part of adaptive research and safety-driven decision-making. In India, the CDSCO provides a structured regulatory pathway for managing such changes through the SUGAM portal and NDCTR framework. Sponsors and investigators must ensure timely, accurate, and transparent submissions to maintain compliance and protect participant rights. Building SOPs around protocol change management ensures operational consistency and regulatory confidence.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

Indian GCP Guidelines vs ICH E6: A Comprehensive Regulatory Comparison

Posted on digi By digi

While Indian GCP guidelines laid a strong foundation for clinical research in the early 2000s, the rapid evolution of trial methodologies and digital ecosystems has created a divergence from international expectations. Sponsors conducting trials in India must bridge this gap by adopting ICH E6(R2)-aligned practices, training their teams comprehensively, and preparing for future updates under NDCTR and upcoming E6(R3). Harmonizing both frameworks ensures ethical integrity, data quality, and global regulatory acceptability.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

Case Studies: FDA Inspections of Indian Clinical Trial Sites

Posted on digi By digi

FDA inspections of Indian clinical trial sites offer critical insights into operational gaps, compliance risks, and the evolving expectations of global regulators. By analyzing real-world case studies, stakeholders can identify red flags early and strengthen systems to ensure ethical, compliant, and globally acceptable trial data. With India’s growing participation in global studies, inspection readiness is no longer optional—it’s a strategic imperative.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

Enhancing Patient Diversity and Recruitment in Indian Clinical Trials

Posted on digi By digi

Patient diversity in Indian clinical trials is both a moral imperative and a scientific necessity. As India plays an expanding role in global clinical research, the responsibility lies with sponsors, investigators, and regulators to ensure that every trial reflects the true diversity of the population it aims to serve. Addressing language, cultural, gender, and geographic barriers is essential to building credible, inclusive, and impactful data sets that benefit all Indians—urban or rural, rich or poor, majority or minority.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

Understanding Insurance Requirements for Clinical Trial Investigators in India

Posted on digi By digi

While not legally mandated, investigator insurance is fast becoming a best practice—and in some cases, a requirement—in Indian clinical trials. With increasing regulatory scrutiny, ethical expectations, and legal awareness, investigators must proactively address their exposure to liability. Whether covered under sponsor policies or through independent plans, adequate insurance safeguards the integrity of trials, protects patients, and ensures investigators can focus on ethical and scientific excellence without fear of litigation or financial risk.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

Mandatory Training and Certification Requirements for Clinical Trial Investigators in India

Posted on digi By digi

Training and certification are not just formalities but critical enablers of quality and compliance in Indian clinical trials. By institutionalizing documented training pathways, maintaining updated certification logs, and aligning with both national and global expectations, Indian investigators and sites can ensure regulatory preparedness, ethical rigor, and successful trial outcomes.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

Risk-Based Monitoring Pilots in Indian Clinical Trials: Trends, Challenges, and Regulatory Outlook

Posted on digi By digi

Risk-Based Monitoring is slowly becoming an integral part of the Indian clinical trial landscape. With evolving digital infrastructure, increasing regulatory comfort, and proven pilot success, RBM offers a pathway to scalable, cost-effective, and quality-driven trial oversight. Sponsors and CROs must invest in training, technology, and stakeholder engagement to realize the full potential of RBM in India’s dynamic research environment.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

Regulatory Framework for Investigator-Initiated Trials in India Explained

Posted on digi By digi

Investigator-Initiated Trials are vital to India’s clinical research ecosystem. However, regulatory responsibilities under NDCTR 2019, ethical obligations under ICMR, and operational demands under GCP must be clearly understood by academic investigators. With structured planning, transparent funding, and strong institutional support, IITs can generate high-quality data that informs clinical practice while upholding participant safety and scientific integrity.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

Role of Indian Contract Manufacturing in Clinical Trials

Posted on digi By digi

Contract manufacturing in Indian clinical trials is no longer limited to cost efficiencies—it is a strategic enabler of speed, compliance, and scalability. With proper licensing, GMP adherence, and sponsor oversight, Indian CDMOs can significantly contribute to global drug development programs while aligning with CDSCO and international expectations. Sponsors must ensure robust due diligence, clear quality agreements, and strong monitoring to leverage the full potential of contract manufacturing in clinical research.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

Clinical Trial Master File Requirements in India

Posted on digi By digi

The TMF is more than a regulatory requirement—it’s a real-time indicator of a trial’s integrity, conduct, and compliance. With growing CDSCO scrutiny and global trial participation, Indian sponsors, CROs, and investigators must embrace standardized, audit-ready TMF practices. Whether managed on paper or electronically, a well-maintained TMF safeguards data credibility, protects patient rights, and ensures long-term regulatory alignment in the dynamic landscape of Indian clinical research.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials